Zealand Pharma A/S
ZEAL.CO$28.69B
Large CapNASDAQBiotechnology🇺🇸North America440 employees
Drugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Apr 15, 2026
9wData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 0 past
⭐Phase 3Next
Glepaglutide Phase 3 Results Expected
April 2026~glepaglutide129
Primary completion for Glepaglutide trial (NCT04881825) in Short Bowel Syndrome
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
dasiglucagon
Congenital Hyperinsulinism
GlucaGen
Hypoglycemia
glepaglutide
Short Bowel Syndrome
Insulin Lispro
Diabetes Mellitus, Type 1
Petrelintide
Overweight
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
dasiglucagon | Phase 3 | Congenital Hyperinsulinism | - |
GlucaGen | Phase 3 | Hypoglycemia | - |
glepaglutide | Phase 3 | Short Bowel Syndrome | - |
Insulin Lispro | Phase 2 | Diabetes Mellitus, Type 1 | - |
Petrelintide | Phase 2 | Overweight | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
ZEAL.CO News